Overview of Desofemono

Desofemono is a specialized oral tablet that contains a synthetic hormone derivative, functioning as a highly effective form of hormonal contraception. Its primary role is the dependable prevention of pregnancy by systematically influencing the female reproductive cycle, a purpose clinically recognized by major health organizations.

Property	Description
Active ingredient	Desogestrel (INN)
Form	Oral tablet
Pharmacological class	Hormonal contraceptive (Progestogen)
Common use	Prevention of pregnancy
Origin	Synthetic hormone derivative

Definition and Pharmacological Classification

Desofemono is classified within the pharmacological class of hormonal contraceptives and is specifically identified as a progestogen. The medicine is presented as an oral tablet, the form ensuring its systemic effect following ingestion. The core ingredient, Desogestrel, is a third-generation progestin. Desogestrel has a clearly defined and effective mechanism for preventing pregnancy.

This classification means the medication operates by introducing a synthetic hormone designed to mimic the biological activity of the natural hormone progesterone. Desofemono is typically prescribed to women of reproductive age seeking a reliable, daily-administered method of birth control.

What is the Active Ingredient in Desofemono?

The exclusive active ingredient in Desofemono is the International Non-proprietary Name (INN) substance, Desogestrel. This progestin is the compound responsible for the medicine's therapeutic action, serving as the sole active agent in specific formulations referred to as progestogen-only pills or in combination products.

Desogestrel achieves contraception primarily by inhibiting ovulation. This effectiveness comes from the ability to stop the monthly release of an egg. Desogestrel is distinguished from older progestins by its high selectivity, a feature supported by pharmacological studies. The inclusion of this powerful synthetic hormone ensures a targeted physiological mechanism—the suppression of ovulation and alteration of the reproductive environment—establishing the medicine as a robust tool for reliable contraception.

Regulatory References

What side effects are possible with Desofemono?

Possible Side Effects and Safety Information

The safety profile of Desofemono (Desogestrel 75 microgram, a progestogen-only contraceptive) is defined by officially documented adverse reactions and risk patterns established through regulatory review. Adverse reactions are classified by frequency and associated System Organ Class (SOC) according to governmental regulatory standards.

Officially Documented Adverse Reactions by Frequency

Adverse effects are categorized based on their reported incidence in clinical data:

Frequency Category	Representative Adverse Reactions
Common (1-10%)	Altered mood, Depressed mood, Headache, Nausea, Acne, Breast pain, Irregular menstruation, Amenorrhoea, Increased weight.
Uncommon (0.1-1%)	Vaginal infection, Migraine, Vomiting, Alopecia (hair loss), Ovarian cyst, Fatigue.

These effects primarily involve the Reproductive System, Nervous System, Psychiatric Disorders, and Gastrointestinal Disorders, as formally classified in regulatory documents.

Serious Systemic Safety Considerations

Regulatory labeling addresses the potential for serious systemic risks associated with hormonal contraceptive use:

Thromboembolic Events: The use of progestogen-only pills, like Desofemono, is considered in the context of the established risk of Venous Thromboembolism (VTE) associated with hormonal contraceptives. Discontinuation is officially noted in the event of a thrombosis.
Malignancies: Safety documents consider the potential impact on the risk of breast cancer and note that a biological effect of progestogens on liver cancer cannot be excluded.

Safety-Related Restrictions and Special Populations

Desofemono is formally restricted for use in individuals with active Venous Thromboembolic Disorder, current or history of Severe Hepatic Disease (until liver function is normal), and known or suspected Sex-Steroid Sensitive Malignancies. While it is not indicated during pregnancy, it may be used during lactation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Desofemono overdose is characterized by low acute toxicity. Ingestion of a dose higher than prescribed is typically associated with non-severe effects, as documented in government labeling.

Domain	Official Regulatory Finding
Documented Manifestations	Nausea, vomiting, and slight vaginal bleeding (withdrawal bleeding) are the principal signs reported in cases of high-dose ingestion.
Acute Toxicity Profile	Regulatory documents explicitly state that no serious harmful effects have been reported following acute overdose of the active ingredient, desogestrel.
Management Constraint	No specific antidote is known for this overdose scenario, requiring that management focuses on clinical support.
Population Note	The occurrence of withdrawal bleeding is specifically noted in young girls who may have accidentally ingested a large dose, as documented in regulatory texts.

Immediate Actions Mandated by Regulatory Authorities

The official prescribing information defines the Desofemono overdose profile as one of low acute toxicity, with reported clinical manifestations limited to mild, non-specific hormonal effects. In the event of ingestion of a significantly large dose, the regulator-mandated action is to seek immediate medical attention. This action is also required if severe, non-specific symptoms occur, such as trouble breathing or chest pain. Treatment provided for an overdose is strictly symptomatic and supportive, reflecting the absence of a known specific antidote. Consistent with general safety procedures for acute drug exposure, hospital monitoring may be required following a significant ingestion to ensure patient stability and complete observation.

Therapeutic Uses of Desofemono

What Desofemono Treats: Main Uses and Benefits

Desofemono is commonly used across two primary therapeutic domains: providing support for fertility management and assisting with symptomatic relief for menstrual health. This progestogen formulation is a relevant option for women who benefit from an estrogen-free alternative.

The primary indication for Desofemono is oral support for fertility management to address the ongoing risk of unintended pregnancy. It is also used for managing symptom groups such as abnormally heavy bleeding (menorrhagia) and associated pelvic pain (dysmenorrhea). The therapeutic benefit centers on offering support that helps patients cope more steadily with fertility management and assists with maintaining functional stability.

This medicine is considered a relevant therapeutic option for women who benefit from reliable fertility management and who benefit from an estrogen-free alternative to combined estrogen pills. This progestogen-only formulation is applied in addressing specific patient needs for groups such as nursing mothers and women with certain cardiovascular risk factors.

Quick Fact: Relief for Menstrual Symptom Burden

Desofemono contributes to improved day-to-day comfort during symptomatic periods and supports patients during difficult episodes by easing distress.

Eligibility and Restrictions for Use

The eligibility for using Desofemono (Desogestrel) is strictly defined by official regulatory labeling, outlining specific populations who are permitted to use the medicine and those who are absolutely excluded.

Populations For Whom Use Is Contraindicated

The medicine must not be used by women who have or have a history of the following conditions, as they are designated as absolute contraindications in official documents:

Active Venous Thromboembolic Disorder (VTE), such as Deep Vein Thrombosis or Pulmonary Embolism.
Severe Hepatic Disease (liver disease) as long as liver function values have not returned to normal.
Known or Suspected Sex-Steroid Sensitive Malignancies, primarily breast cancer.
Undiagnosed Abnormal Vaginal Bleeding (must be investigated before starting therapy).
Known or Suspected Pregnancy; use must be stopped immediately if detected.
Hypersensitivity to the active substance or any excipients.

Eligible Populations and Age Rules

Desofemono is intended for use by women of reproductive age seeking contraception. It is commonly permitted for use in breastfeeding women, as progestogen-only pills are often preferred over combined oral contraceptives in this group. While use is approved in post-menarche adolescents, it is not established for pre-menarche children or not indicated for post-menopausal older adults. Patients with renal impairment are generally permitted to use the medicine, as no specific restriction is mandated in regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Desofemono (Desogestrel) interacts with several medicinal products and substances, primarily by mechanisms that affect its concentration in the body, leading to the risk of reduced contraceptive protection.

Documented Pharmacokinetic Interactions

Many interactions are classified as pharmacokinetic, involving agents that accelerate the breakdown of the active hormone through enzyme induction. This reduces the exposure of the active metabolite, etonogestrel. Medicines officially documented to cause this interaction pattern include the anticonvulsants phenytoin, carbamazepine, phenobarbital, and primidone. Anti-infective agents like rifampicin and griseofulvin, as well as the HIV treatment ritonavir, are also listed as causing a decrease in contraceptive efficacy through similar metabolic interference.

Interaction-Related Restrictions and Constraints

Official regulatory documents require that Desofemono be discontinued before initiating treatment with the Hepatitis C virus (HCV) combination drug regimen of ombitasvir/paritaprevir/ritonavir (with or without dasabuvir). Desogestrel is also documented to interfere with the clearance of other medicines, potentially causing an increase in the plasma levels of Cyclosporine and a decrease in the levels of Lamotrigine.

Interactions with Other Products

The herbal product St. John’s Wort ( extitHypericum perforatum) is officially documented to interact with Desogestrel via enzyme induction, potentially reducing its contraceptive effect. Additionally, medical charcoal is listed as a substance that may interfere with the drug’s action.

Mechanism of Action

Desofemono (Desogestrel) acts via its active metabolite, etonogestrel, a synthetic progestin that modulates core reproductive pathways by binding to the progesterone receptor (PR). The drug's activity profile is achieved through a dual mechanism involving central and peripheral actions.

Central Inhibition of the Ovulatory Cascade

This domain addresses the drug's primary action on the hypothalamic-pituitary-ovarian (HPO) axis, where it engages negative feedback mechanisms. By modulating specific hormonal signals, etonogestrel suppresses the Luteinizing Hormone (LH) surge, inhibiting the final cascade that triggers the release of an ovum.

Peripheral Modulation of the Reproductive Environment

This mechanism involves modulation of progesterone receptor activity in peripheral tissues of the reproductive tract. The progestin alters the consistency of the cervical mucus, causing it to become significantly thicker and less permeable. This results in reduced permeability, influencing the progression of spermatozoa.

Endometrial Signaling Adjustment

Etonogestrel also engages regulatory feedback mechanisms within the endometrium (uterine lining). By modulating PR activity in this tissue, it induces changes that result in a thinner, atrophic lining. This effect alters the endometrial environment, leading to a modified tissue state within the pathway.

Dosage and Administration Information

How to Use Desofemono

The usage of Desofemono (Desogestrel 75 microgram oral tablet) follows a continuous daily regimen, ensuring a consistent administration pattern.

Administration Scope and Schedule

Instruction Category	Official Guideline
Route of administration	The medicine is administered via the oral route (swallowed whole).
Dosing schedule	One 75 microgram tablet must be taken daily, ensuring a consistent dose and continuous exposure.
Frequency and Schedule	The tablet must be taken once daily at about the same time each day, which maintains the required 24-hour interval between doses.
Course Duration	The regimen is continuous, requiring the user to immediately start a new pack of 28 tablets without a tablet-free break.

Procedural Administration Rules

There are specific instructions for managing deviations from the daily schedule, as well as guidance for initiating the first dose.

Missed Dose Rule: If the daily dose is missed by less than 12 hours, the tablet should be taken immediately. If missed by more than 12 hours, an additional barrier method is required for the subsequent seven days.
Initiation: The medicine is typically started on the first day of the menstrual cycle. Specific procedures also govern the timing of the first dose in the postpartum period (21 to 28 days post-delivery) or following an abortion.
Tablet Intake: The tablet is swallowed whole, and administration must be continued daily without interruption, even if vaginal bleeding occurs.

Recent Clinical Evidence

Desofemono is a hypothetical name used to represent a progestogen-only contraceptive agent (similar to desogestrel 75 mug) that is researched primarily for its effect on ovulation inhibition.

Clinical Efficacy and Mechanism

Research into this class of progestogen-only pills suggests a highly potent effect on the hypothalamic-pituitary-ovarian axis. Clinical trials indicate that a daily dose can lead to the suppression of ovulation in approximately 97% of observed cycles, a notably high rate compared to some older progestogen-only formulations. This high rate of ovulation inhibition is considered the main factor contributing to its contraceptive effect.

Contraceptive Effectiveness and Comparisons

The contraceptive effectiveness of the 75 mug dose, when measured by the Pearl Index (a measure of pregnancies per 100 woman-years of use), has been reported in the range of 0.14 to 0.41. In comparative double-blind studies, this agent demonstrated a lower Pearl Index (indicating potentially fewer unintended pregnancies) compared to the levonorgestrel 30 mug progestogen-only pill, although some trial data suggest the difference in overall contraceptive efficacy may not be statistically significant across all studies.

Bleeding Patterns and Acceptability

Changes in the menstrual bleeding pattern are a well-documented effect. Early use may be associated with increased variable bleeding, spotting, or frequent bleeding episodes. However, long-term observation (up to 12 months) suggests a tendency toward infrequent bleeding or amenorrhea (absence of bleeding) in a significant proportion of users, which may be higher than observed with older progestogen-only pills. Overall acceptability in trials appears comparable to or slightly higher than other progestogen-only contraceptives.

Frequently Asked Questions (FAQ)

Common questions about Desofemono (FAQ)

Q: How quickly does Desofemono start to work?

Official prescribing information indicates that if the medicine is started on the first day of the menstrual cycle, protection is considered effective immediately. If the start day is delayed to days 2–5 of the cycle, an additional barrier method is recommended for the first seven days of tablet-taking. This guidance is detailed in the official administration instructions.

Q: Can Desofemono be used long-term?

The official regulatory regimen for this medicine is described as continuous daily use, which suggests ongoing treatment. Regulatory documents note the importance of having progress checked at regular intervals, typically every 6 to 12 months, to monitor its use and any potential long-term effects. This process allows a healthcare provider to assess ongoing suitability.

Q: Does taking Desofemono affect fertility after stopping the medicine?

Official guidance on discontinuation indicates that a return to fertility may occur soon after stopping the medicine. There is no recommended 'washout period.' For some individuals, the menstrual cycle and natural rhythm may take a few months to fully re-establish themselves.

Q: Is Desofemono available generically or only as a brand name?

The active ingredient in this medicine, Desogestrel 75 mug, is available in various formulations under multiple brand and generic names worldwide. The specific name used depends on the local country’s specific regulatory approvals and market availability.

Q: Is Desofemono still effective if I have vomiting or diarrhea?

Official guidance states that if vomiting or severe diarrhea occurs within 3–4 hours of taking a tablet, the medicine may not have been fully absorbed. This situation is considered equivalent to a missed dose. In this event, official guidance recommends following the specific procedures for a missed dose to support continued contraceptive protection.

Q: Does Desofemono change cholesterol levels?

Studies have shown that some hormonal contraceptives may affect blood lipid profiles, including levels of HDL cholesterol and triglycerides. Official clinical data for this medicine notes that changes in these levels have been observed. However, the exact clinical significance of these changes for the individual is not always explicitly defined in the product label.

Q: Is there a known effect of Desofemono on bone density?

The medicine causes a decrease in estradiol serum levels, which reflects the body’s hormonal changes during the early follicular phase. Regulatory documents state that it is currently unknown whether this reduction in estrogen levels has a clinically relevant impact on bone mineral density over time.

Q: Where can I find the official patient leaflet for Desofemono?

The official Patient Information Leaflet (PIL) or Medication Guide is dispensed with the medicine pack. Digital copies of this document can also be found on the websites of national regulatory bodies. These resources include the FDA DailyMed or the European Medicines Agency (EMA), typically found by searching for the active ingredient, Desogestrel.

Q: Is Desofemono licensed for use in men?

According to official regulatory documents, this medicine is not licensed for use in men. The approved therapeutic indication for this product is exclusively for female contraception within the labeled population.

Q: Can Desofemono affect blood pressure readings?

Official prescribing information notes caution is advised when the medicine is used in patients with existing hypertension (high blood pressure). Significant, confirmed increases in blood pressure are cited as a reason for potential discontinuation of the medicine, and regular blood pressure monitoring may be necessary.

Q: Do I need regular check-ups while taking Desofemono?

Regulatory documents note that checking the user's progress at regular visits is important. These check-ups are typically recommended every 6 to 12 months. This process is intended to monitor the ongoing effectiveness of the medicine and to check for any potential adverse effects.

Q: Is it possible for Desofemono to interfere with laboratory blood tests?

Official product information notes that hormonal contraceptives can interfere with the results of certain laboratory tests. This interference may affect tests that measure hepatic function (liver function) and parameters related to coagulation (blood clotting) parameters.

Q: Are there different strengths or versions of Desofemono?

This specific medicine, Desofemono, is the 75 microgram oral tablet formulation of Desogestrel. This is the standard strength for this anti-ovulatory progestogen-only pill type. Other progestin-only pills available may contain different active ingredients or different doses.

Q: What is the difference between Desofemono and other similar drugs?

Official data suggests the medicine differs from older progestin-only 'minipills' because its main mechanism is the highly potent inhibition of ovulation. This contrasts with older versions that primarily thickened cervical mucus. It is also an important option for women who are unable to use estrogen-containing medicines due to medical restrictions.

Q: What happens if Desofemono is taken at different times each day?

Official prescribing information advises taking the tablet at about the same time each day to maintain consistent hormone levels. If the tablet is taken more than 12 hours late, contraceptive protection may be compromised. In this instance, official instructions recommend the use of an additional barrier method for the following seven days.

Q: Is Desofemono safe to use if I have a history of migraines?

The prescribing information lists migraine as an uncommon side effect. Regulatory guidance notes that progestin-only pills are sometimes considered when combination pills are not an option for individuals with certain migraine concerns. Official guidance cites certain severe migraine events as a reason for potential discontinuation of the medicine.

Q: What official guidance exists on taking Desofemono with antibiotics?

The official label only details interactions with specific enzyme-inducing anti-infective medicines, such as rifampicin. The effectiveness of the medicine is generally not considered significantly impaired by most common, non-enzyme-inducing antibiotics. However, if any antibiotic leads to vomiting or severe diarrhea, official guidance recommends following the special instructions for a missed dose.

Q: What is the significance of the research evidence for Desofemono?

Studies and official information highlight that the evidence for this medicine is based on its high rate of ovulation suppression, which occurs in approximately 97% of observed cycles. This high suppression rate is a key finding that suggests a high degree of contraceptive efficacy compared to some older progestogen-only formulations.

Q: Why do doctors often prescribe Desofemono over other options?

Comparative studies indicate that this medicine has a high rate of ovulation inhibition and a lower Pearl Index than some older progestin-only pills, suggesting a high level of efficacy. Furthermore, regulatory guidelines describe it as being useful for individuals who have medical restrictions that prevent the use of estrogen-containing medicines, such as a history of Venous Thromboembolism (VTE) or high blood pressure.

Q: Is Desofemono affected by prolonged exposure to heat or cold?

Official regulatory instructions note the medicine must not be stored at temperatures above 30 C and is required to be protected from light and moisture. Exposure to temperatures exceeding this limit or prolonged deviation from the ideal storage conditions may compromise the product's stability and effectiveness.

Q: How does the mechanism of Desofemono differ from estrogen-containing medicines?

Desofemono is a progestin-only medicine, meaning it contains no estrogen. Its contraceptive efficacy is achieved through the powerful inhibition of ovulation. In contrast, combined oral contraceptives use estrogen to enhance hormonal suppression and aid in regulating the user's menstrual bleeding patterns.

Q: Are there any long-term research studies on the use of Desofemono?

Official clinical trial data on this medicine includes long-term observation periods for various factors. These studies, which have extended up to 12 months, were designed to assess changes in bleeding patterns and the overall tolerability and acceptability of the medicine among users.

Q: Is Desofemono described as being metabolized in the liver?

Official pharmacological documents state that the active substance, Desogestrel, is rapidly converted into its active metabolite, etonogestrel, through a process of metabolism. This process relies on liver function, which is confirmed by the official contraindication against its use in individuals with Severe Hepatic Disease.

Q: What happens if the tablet is chewed or dissolved instead of swallowed whole?

The official instructions require the tablet to be swallowed whole. Official guidance does not advise chewing or crushing the tablet, as this can disrupt its intended absorption profile. Manipulating the tablet in this way may lead to an altered release of the dose and a potential reduction in the medicine's contraceptive effectiveness.

How should Desofemono be stored and disposed of?

Official Storage and Disposal Requirements

Desofemono (Desogestrel oral tablets) must be stored and disposed of according to specific, officially documented regulatory requirements to ensure product stability and environmental protection. No information regarding dosage, benefits, or how the medicine works is included in these instructions.

Requirement Area	Official Regulatory Statement
Temperature	Do not store at temperatures above 30 C.
Protection	Store the blister pack in the original sachet to protect from light and moisture.
Stability	Use within 1 month from the date the original sachet is first opened.
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal Rule	Do not throw away unused or expired medicine via wastewater or household waste.
Disposal Mandate	Dispose of the product in accordance with local regulatory requirements.

Desofemono